Sven Rottenberg

14.0k citations

98 papers · 6.4k indexed · 3 hit papers · h-index 34

Impact in

Oncology top 0.5%
- PARP inhibition in cancer therapy
- Cancer Cells and Metastasis
Molecular Biology top 1%
- DNA Repair Mechanisms
- CRISPR and Genetic Engineering
- Cancer therapeutics and mechanisms

Papers in

Oncology 46
- PARP inhibition in cancer therapy 30
- Drug Transport and Resistance Mechanisms 7
Cancer Research 15
- Cancer Genomics and Diagnostics 9

Co-authors: Jos Jonkers Piet Borst Carmen A. Widmer Paola Perego Janneke E. Jaspers Ariena Kersbergen Anders O.H. Nygren Serge A.L. Zander
Journals: Cancer Research (7 papers)Drug Resistance Updates (5 papers)Nature Communications (4 papers)Proceedings of the National Academy of Sciences (4 papers)Molecular Cell (3 papers)
Partner nations: Switzerland Netherlands United Kingdom

In The Last Decade

Sven Rottenberg

94 papers receiving 6.3k citations

Hit Papers

align trajectories log scale

The rediscovery of platinum-based cancer therapy 2020 · 670 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 Nature reviews. Cancer
2019 Cancer Discovery
2008 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Sven Rottenberg

Since Specialization

Citations

This map shows the geographic impact of Sven Rottenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven Rottenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven Rottenberg more than expected).

Fields of papers citing papers by Sven Rottenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sven Rottenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven Rottenberg. The network helps show where Sven Rottenberg may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Sven Rottenberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sven Rottenberg Line = papers co-authored together Sven Rottenberg links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Individualized Pooled CRISPR/Cas9 Screenings Identify CDK2 as a Druggable Vulnerability in a Canine Mammary Carcinoma Patient Veterinary Sciences ·Besiroglu Huseyin, Martina Dettwiler, Chang He, Enni Markkanen, Lennart Opitz, Arunasalam Naguleswaran, Sven Rottenberg	2025	0
2	The PIN1–p38–CtIP signalling axis protects stalled replication forks from deleterious degradation Nucleic Acids Research ·Anthony D.; id_orcid 0000-0001-8083-7633 Fox, Marco Gatti, Low Zhe Xuan, Hülya Doğan, Antônio Porro, Eveline Hipeli, Ilaria Ceppi, SQ Nizami, A Stratton Vice-Prtsiienu, I. A. Stepanovskaya, Martin Steger, Begoña Cánovas, Monica Cubillos‐Rojas, Antoni Riéra, Petr Ćejka, Ángel R. Nebreda, Diego Dibitetto, Sven Rottenberg, Alessandro A. Sartori	2025	0
3	Persisting cancer cells are different from bacterial persisters Trends in cancer ·Vaibhav Y. Javale, Sven Rottenberg	2024	6
4	Establishment of Primary Cell Cultures from Canine Oral Melanomas via Fine-Needle Aspiration: A Novel Tool for Tumorigenesis and Cancer Progression Studies Animals ·Haimera Workie, Ilaria Porcellato, Qiangming Liu, Sven Rottenberg, Chang He, Seunghwa Chung, 元彦近藤, Monica Cagiola, Luca Mechelli, Elisabetta Chiaradia, Chiara Brachelente	2024	1
5	Host cell CRISPR genomics and modelling reveal shared metabolic vulnerabilities in the intracellular development of Plasmodium falciparum and related hemoparasites Nature Communications ·義雄中瀬, María Masid, Kerry Woods, Reto Caldelari, John G. Doench, Arunasalam Naguleswaran, Koun Kim, Nariman Javan, Roof, M.E. Ajayi Coomber, Vassily Hatzimanikatis, Volker T. Heussler, Sven Rottenberg, Philipp Olias	2024	2
6	Artificial Intelligence to Predict the BRAF V595E Mutation in Canine Urinary Bladder Urothelial Carcinomas Animals ·Mahesh kumaar R, A. Prahl, Reem Mahmoud Mohamed Abdelbasit, Franco Guscetti, Louise van der Weyden, Wolf von Bomhard, Eberhard Pflueger, 横水康伸, Heike Aupperle‐Lellbach, Alexandra Kehl, Sven Rottenberg, Simone de Brot	2023	7
7	CRISPR/Cas9-Mediated Targeting of BPV-1-Transformed Primary Equine Sarcoid Fibroblasts Viruses ·N T SPECK, Christoph Koch, Christoph Jindra, Maarten Haspeslagh, Hannah Fazio, Christian Wenker, Vinzenz Gerber, Sven Rottenberg, Kerstin Hahn	2023	1
8	Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy Cancer Research Communications ·Carmen A. Widmer, Ota Kukral, Nazaad Baksh, Vaibhav Y. Javale, Hannah Fazio, Keyling Jurielma Moreno Tórrez, Paul Essers, Zuzanna Nowicka, Nadine Stokar‐Regenscheit, Marieke van de Ven, Renske de Korte‐Grimmerink, José A. Galván, Colin E.J. Pritchard, Ivo J. Huijbers, Wojciech Fendler, Conchita Vens, Sven Rottenberg	2022	9
9	Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors Cancer Research ·Marco Barazas, Alessia Gasparini, Yike Huang, Aslι Küçükosmanoğlu, Stefano Annunziato, Peter Bouwman, Wendy Sol, Ariena Kersbergen, Natalie Proost, Renske de Korte‐Grimmerink, Marieke van de Ven, Jos Jonkers, Gerben R. Borst, Sven Rottenberg	2018	36
10	Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice Clinical Cancer Research ·Marina Pajic, Sohvi Blatter, Charlotte Guyader, Maaike Gonggrijp, Ariena Kersbergen, Aslι Küçükosmanoğlu, Wendy Sol, Rinske Drost, Jos Jonkers, Piet Borst, Sven Rottenberg	2017	20
11	The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models Cancer Research ·Lenka Oplustil O’Connor, Stuart L. Rulten, Aaron Cranston, Rajesh Odedra, H. Shelton Brown, Janneke E. Jaspers, 博之野海, Charlotte Knights, Bastiaan Evers, Attilla Ting, Robert H. Bradbury, Marina Pajic, Sven Rottenberg, Jos Jonkers, Delia Marwah Azizah, Niall M.B. Martin, Keith W. Caldecott, Alan Lau, Mark J. O’Connor	2016	60
12	BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance Cancer Research ·Janneke E. Jaspers, Wendy Sol, Ariena Kersbergen, Andreas Schlicker, Charlotte Guyader, Guotai Xu, Lodewyk F.A. Wessels, Piet Borst, Jos Jonkers, Sven Rottenberg	2014	53
13	Identifying subgroup markers in heterogeneous populations Nucleic Acids Research ·Jorma J. de Ronde, Guillem Rigaill, Sven Rottenberg, Sjoerd Rodenhuis, Lodewyk F.A. Wessels	2013	16
14	Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors Cancer Discovery ·Janneke E. Jaspers, Ariena Kersbergen, Ute Boon, Wendy Sol, Liesbeth van Deemter, Serge A.L. Zander, Rinske Drost, Ellen Wientjens, Jiuping Ji, Beyza Kavalci, James H. Doroshow, Aaron Cranston, Niall M.B. Martin, Alan Lau, Mark J. O’Connor, Shridar Ganesan, Piet Borst, Jos Jonkers, Sven Rottenberg	2012	388
15	Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol Cancer Prevention Research ·Serge A.L. Zander, Ariena Kersbergen, Wendy Sol, Maaike Gonggrijp, Koen van de Wetering, Jos Jonkers, Piet Borst, Sven Rottenberg	2012	13
16	6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance Cancer Research ·Natalia Issaeva, Huw D. Thomas, N. Macfadyen, Janneke E. Jaspers, Ivaylo Stoimenov, Suzanne Kyle, Nicholas Pedley, Ponnari Gottipati, Rafal Zur, Kate Sleeth, A. Capoccia, Evan A. Mulligan, Cecilia Lundin, AZM Rayhanur Rahman, Ariena Kersbergen, Adrian L. Harris, Ricky A. Sharma, Sven Rottenberg, Nicola J. Curtin, Thomas Helleday	2010	80
17	Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan Cancer Research ·Serge A.L. Zander, Ariena Kersbergen, Eline van der Burg, Chung Hsien Chou, Olaf van Tellingen, Alexander T. Galt Galt, Janneke E. Jaspers, Marina Pajic, Anders O.H. Nygren, Jos Jonkers, Piet Borst, Sven Rottenberg	2010	66
18	Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer Cancer Research ·Marina Pajic, Jayasree K. Iyer, Ariena Kersbergen, Eline van der Burg, Anders O.H. Nygren, Jos Jonkers, Piet Borst, Sven Rottenberg	2009	77
19	Therapeutic options for triple-negative breast cancers with defective homologous recombination Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·Janneke E. Jaspers, Sven Rottenberg, Jos Jonkers	2009	31
20	Hijacking of Host Cell IKK Signalosomes by the Transforming Parasite Theileria Science ·Volker T. Heussler, Sven Rottenberg, R. Schwáb, Peter Küenzi, Paula Fernández, Susan McKellar, Brian Shiels, Zhijian J. Chen, Kim Orth, David Wallach, D. Dobbelaere	2002	118

About Sven Rottenberg

Sven Rottenberg is a scholar working on Oncology, Cancer Research, Molecular Biology, Parasitology and Biotechnology, having authored 98 papers that have together received 6.4k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (37 papers), PARP inhibition in cancer therapy (30 papers), CRISPR and Genetic Engineering (19 papers), Cancer Genomics and Diagnostics (9 papers), BRCA gene mutations in cancer (7 papers), Cancer therapeutics and mechanisms (7 papers), Veterinary Oncology Research (7 papers) and Drug Transport and Resistance Mechanisms (7 papers). The work is most often cited by research in Oncology (3.6k citations), Molecular Biology (4.2k citations), Cancer Research (827 citations), Reproductive Medicine (332 citations) and Immunology (702 citations). Sven Rottenberg has collaborated with scholars based in Switzerland, Netherlands and United Kingdom. Frequent co-authors include Jos Jonkers, Piet Borst, Carmen A. Widmer, Paola Perego, Janneke E. Jaspers, Ariena Kersbergen, Anders O.H. Nygren, Serge A.L. Zander, Mark J. O’Connor and Niall M.B. Martin. Their work appears in journals such as Cancer Research, Drug Resistance Updates, Nature Communications, Proceedings of the National Academy of Sciences and Molecular Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact